By otakuyassine3@gmail.com 
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report released on Tuesday,Benzinga reports. They currently have a $52.00 price objective on the stock. Wedbush’s price target would indicate a potential upside of 99.62% from the stock’s previous close.
Other research analysts also recently issued research reports about the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, September 24th. Leerink Partners cut shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $41.00 to $27.00 in a research note on Tuesday, November 5th. Stifel Nicolaus upped their price objective on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Citigroup decreased their target price on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th. Finally, Oppenheimer restated an “outperform” rating and set a $53.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $53.67.
Get Our Latest Report on IDEAYA Biosciences
IDEAYA Biosciences Stock Up 3.4 %
IDYA stock opened at $26.05 on Tuesday. IDEAYA Biosciences has a 52 week low of $24.72 and a 52 week high of $47.74. The company has a fifty day simple moving average of $28.66 and a two-hundred day simple moving average of $34.30. The firm has a market capitalization of $2.25 billion, a P/E ratio of -11.18 and a beta of 0.79.
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same quarter in the previous year, the company posted ($0.46) earnings per share. As a group, analysts anticipate that IDEAYA Biosciences will post -2.45 EPS for the current year.
Institutional Trading of IDEAYA Biosciences
Several institutional investors and hedge funds have recently modified their holdings of the business. KBC Group NV lifted its holdings in shares of IDEAYA Biosciences by 29.1% in the third quarter. KBC Group NV now owns 2,274 shares of the company’s stock valued at $72,000 after purchasing an additional 513 shares in the last quarter. Amalgamated Bank lifted its stake in shares of IDEAYA Biosciences by 22.9% during the third quarter. Amalgamated Bank now owns 2,840 shares of the company’s stock valued at $90,000 after buying an additional 530 shares during the period. US Bancorp DE lifted its stake in shares of IDEAYA Biosciences by 67.2% during the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after buying an additional 689 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of IDEAYA Biosciences by 35.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company’s stock valued at $94,000 after buying an additional 796 shares during the period. Finally, Allworth Financial LP lifted its stake in shares of IDEAYA Biosciences by 800.0% during the third quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 800 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.
IDEAYA Biosciences Company Profile
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Read More
Receive News & Ratings for IDEAYA Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IDEAYA Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.